Pharmaceutical M&A deals in 2011

Company

Takeover candidate

Deal Value US $ *

Completed

Abcam (UK)

MitoSciences (UK)

Undisclosed

May-11

Abcam (UK)

Ascent Scientific (UK)

$15.9 million

Sep-11

Acino Pharma (Switz)

Mepha (Switz) MENA, Latin America and Asia business units from Teva subsidiary Cephalon

$226.0 million

Dec-11

ADVENTRX Pharma (US)

SynthRx (US)

Undisclosed stock deal

Apr-11

Affymetrix (US)

eBioscience (US)

$330.0 million

Dec-11

Alere (US)

Axis-Shield (UK)

$365.0 million

Bid announced July; Alere went hostile Aug 5; closed Nov 2011

Alexion Pharma (US)

Taligen Therapeutics (US)

$111.0 million

Feb-11

Alexion Pharma (US)

Enobia Pharma (Canada)

$610.0 million upfront and $470 million contingent on regulatory milestones

Exp 1st-qtr 2012

Alkermes (US)

Elan Drug Technologies unit of Elan Corp (Ireland)

$960 million cash and stock deal

Sep-11

Allergan (US)

Vicept Thera (US)

$275.0 million, of which $75 mill upfront

Jul-11

Allozyne (US)

Poniard Pharma (US)

Stock exchange deal

Announced June 23. Deal called off Dec 2011

Amgen (US)

BioVex (US)  

$1.0 billion. Paid $435 million upfront with further $575 million in milestones

Mar-11

Amgen (US)

Bergamo (Brazil)

$215.0 million

Apr-11

Ancient Pharma (US)

Timm Medical (US)

Undisclosed

Jan-11

Apricus Biosciences (US)

US subsidiary of Topotarget A/S (Denmark)

$2.0 million plus $2 million stock based on milestones

Dec-11

Asahi Kasei Pharma (Japan)

Artisan Pharma (US)

Undisclosed

Nov-11

Astellas (Japan)

Perseid Therapeutics (US) Buys Maxygen's stake in JV

$76.0 million

May-11

AstraZeneca (UK)

Guangdong BeiKang Pharma (China)

Undisclosed

Exp 1st-qtr 2012

Axcan (Canada)

Mpex (US)

$230.0 million

Nov-11

Baxter Int (US)

Prism Pharma (US)

$388.0 million of which $170 million upfront

June 2-011

Baxter Int (US)

Baxo Corp (US)

$380.0 million

Nov-11

Baxter Int (US)

Synovis Life Technologies (US)

$325.0 million

Exp 1st-qtr 2012

Biostar Pharma (US)

Shaanxi Weinan (China)

$9.6 million stock deal

Oct-11

Biotie Thera (Finland)

Synosia Thera (Switz)

$121.5 million

Feb-11

Biotie Thera (Finland)

Newron Pharma (Italy)

$60.8 million

Deal cancelled

BioTime (US)

Glycosan Bio Systems (US)

Undisclosed stock deal

Mar-11

BioTime (US)

Cell Targeting (US)

Undisclosed stock deal

Jan-11

Bluefish Pharma (Sweden)

BMM Pharma unit of Medivir (Sweden)

$6.0 million

Aug-11

Bristol-Myers Squibb (US)

Amira Pharma (US)

$325.0 million plus $150.0 million milestones

Sep-11

Celesio (Germany)

OncoProd (Brazil) 60% stake

Undisclosed

Oct-11

Cephalon (US)

Gemin X Pharma (US)

$225.0 million plus milestones of up to $300 million

2011

Cephalon (US)

ChemGenex (Australia)

$231.0 million

2011

Cornerstone Therapeutics (US)

Cardiokine (US)

Undisclosed

Dec-11

Cubist Pharma (US)

Adolor Corp (US)

$221 upfront plus contingent payment right worth up to $225 million

Dec-11

Cynapsus Therapeutics (Canada)

Adagio Pharma (Canada)

$5.55 million

Dec-11

Daiichi Sankyo (Japan)

Plexxikon (US)

$805.0 million

Apr-11

Elan (Ireland)

Proteostasis Therapeutics (US)

$20.0 million for 24% equity stake

May-11

Endo Pharma (US)

American Medical Systems (US)

$2.9 billion

Jun-11

Evotec (Germany)

Kinaxo (Germany)

$17 million

Apr-11

Ewopharma (Swiss)

Newport Pharma subsid of Immdal (Ireland)

Undisclosed

Oct-11

Farmsintez (Russia)

Kevelt (Estonia)

Undisclosed

Jan-11

Ferring Pharma (Swiss)

Cytokine PharmaSciences (US)

Undisclosed

Oct-11

Footstar (US)

CPEX Pharma (US)

$76.6 million

Apr-11

Forest Labs (US)

Clinical Data (US)

$1.2 billion

Apr-11

Fosun Pharma (China)

Aleph Biomed (China) 75% stake

$102.0 million

Feb-11

Galenica (Switz)

Vifor Uriach, the joint venture with Grupo Uriach (Spain)

Undisclosed

Nov-11

Gilead Sciences (US)

Calistoga Pharma (US)

$375.0 million plus possible $225 million in milestones

Apr-11

Gilead Sciences (US)

Pharmasset (US)

$11.0 billion

Exp 1st-qtr 2011

Grifols (Spain)

Talecris Biotherapeutics (US)

$3.4 billion

Jun-11

Hikma Pharma (Jordan)

Unimark Remedies (India) - 25% stake

$33.3 million

May-11

Hikma Pharma (Jordan)

Baxter injectable generics business

$112.0 million (First announced in 2010)

May-11

Hikma Pharma (Jordan)

Hubei Haosun (China) minority stake

$5.0 million

2011

Hikma Pharma (Jordan)

Promopharm (Morocco)

$111.2 million for 63.9% stake; intends to buy remainder

Due end Jan 2012

Histogenics (US)

ProChon Biotech (Israel)

Undisclosed stock-for-stock deal

May-11

Intrexon (US)

Immunologix (US)

Undisclosed

Oct-11

IS Pharma (UK)

Helsinn Healthcare (Switz) Helsinn Birex unit in Ireland

$6.0 million

Feb-11

Jazz Pharma (US)

Azur Pharma (Irish)

All stock merger with Jazz shareholders owning nearly 80% 

Dec-11

Johnson & Johnson (US)

Synthes (Switz)

$21.3 billion

EU Commission launched investigation Nov 2011, decision due Apr 2012

Johnson & Johnson (US)

J&J-Merck Consumer (US). Buys Merck & Co's 50% stake in JV

$175.0 million

Sep-11

Kyowa Hakko Kirin (Japan)

ProStrakan (UK)

$474.3 million

Apr-11

Kohlberg Kravis Roberts (US)

Capsugel (US) a unit of Pfizer

$2.38 billion

Aug-11

Ligand Pharma (US)

CyDEX Pharma (US)

$31.2 million, plus contingent payments

Jan-11

Eli Lilly (US) Elanco unit

Janssen Pharma animal health business

Undisclosed

Jul-11

Lupin (India)

I'rom Pharma unit of I'rom Holdings (Japan)

Undisclosed

Nov-11

Medicis (US)

Graceway Pharma (US)

$455.0 million

Dec-11

Medivir (Sweden)

BioPhausia (Sweden)

$90.8 million

Jun-11

Merck & Co (US)

Inspire Pharma (US)

$430.0 million

May-11

Merck KGaA (Germany)

Beijing Skywing (China)

$18.2 million

Jan-11

Merck KGaA (Germany)

Microbiology business of Biotest AG (Germany)

Undisclosed

Aug-11

Menarini (Italy)

Invida (Singapore)

Undisclosed)

Nov-11

Mitsui & Co (Japan)

Mercian (Japan) pharma and chemical business

Undisclosed

Jun-11

NeoStem (US)

Progenitor Cell Therapy (US)

About $20.0 million

Oct-11

Nitto Denko (Japan)

Avecia Biotech (US)

Undisclosed

Feb-11

Novartis (Switz)

Genoptix (US)

$470.0 million

Jun-11

Novartis (Switz)

Zhejiang Tianyuan (China) - 85% stake

$125.0 million

Mar-11

Novelos Thera (US)

Cellectar (US)

Stock deal

Apr-11

Nycomed (Switz)

Lab Farmacol (Colombia)

Undisclosed

Jun-11

OPKO Health (US) - controlled by Teva

FineTech Pharmaceutical (Israel)

$27.5 million

Dec-11

Paladin Labs (Canada)

Labopharm (Canada)

$20.6 million

Oct-11

Par Pharmaceutical (US)

Edict Pharmaceuticals (India)

$37.6 million plus assumption of debt

Nov-11

Par Pharma (US)

Anchen Pharma (US)

$410.0 million

Nov-11

Perrigo (US)

Paddock Labs (US)

$540.0 million

Jul-11

Pfizer (US)

Ferrosan (Denmark) Consumer health unit

Undisclosed

Dec-11

Pfizer (US)

Icagen (US)

$56.0 million enterprise value

Oct-11

Pfizer (US)

Excaliard Pharma (US)

Undisclosed

Dec-11

Pharmstandard (Russia)

PJSC Biolek (Russia)

Undisclosed

Jan-11

Qiagen (Netherlands)

Cellestis (Australia)

$355.0 million

Sep-11

Qiagen (Netherlands)

Ipsogen (France)

$101.0 million

Jul-11

Recordati (Italy)

Frik Ilac (Turkey)

$130 million

Sep-11

Repligen (US)

Novozymes Biopharma Sweden unit of Denmark's Novozymes

$22.7 upfront and $5.6 million milestones

Dec-11

Roche (Swiss)

PVT Probenverteiltecknik (Germany)

$90.0 million, plus performance-related milestone

May-11

Roche (Swiss)

mtm laboratories (Germany)

$268.4 million

Aug-11

Roche (Swiss)

Anadys Pharma (US)

$230.0 million

Nov-11

Rxi Pharma (US)

Apthera (US)

$7.2 million plus milestones

Apr-11

Salix Pharma (US)

Oceana Therapeutics (US)

$300.0 million

Dec-11

Sanofi (France)

Genzyme (US)

$21.1 billion plus CVR

Apr-11

Sanofi (France)

OTC business of Universal Medicare (India)

$100 million (Est)

Nov-11

Santen Pharma (Japan)

Novagali (France)

50.55% stake with aim of buying remained for around $135 million

First tranche completed Oct 2011

SciClone Pharma (US)

NovaMed Pharma (China)

$104.8 million cash and shares, with $61.8 upfront

Apr-11

Shire (Ireland)

Advanced BioHealing (US)

$750.0 million

Jun-11

Sinclair IS (UK)

Advanced Bio-Technologies (US)

$32.8 million

Ann Dec 8, close exp 1st-qtr 2011

Sinclair Pharma (UK)

IS Pharma (UK)

Est $208 million stock deal merger

2011

SOHM (US)

Novatrend Medicament (India)

Undisclosed

Nov-11

STADA Arzneimittel (Germany)

Generics business of Spirig Pharma (Switz)

$109.2 million

Exp 1st-qtr 2012

Sucampo Pharma (US)

Sucampo AG (Switz) and Sucampo AG Japan (Japan)

$80.0 million

Jan-11

Sun Pharma (India)

Caraco Pharma (US) Remaining 24.2% shares

$5.25/share

Jun-11

SuperGen (US)

Astex Therapeutics (UK)

$25.0 million plus $30 million deferred

Jul-11

Synageva BioPharma (US)

Trimeris (US)

All stock deal for Trimeris which has market cap of $63.6M

Jul-11

Takeda (Japan)

Fate Therapeutics (US) Unspecified stake

Undisclosed

May-11

Takeda (Japan)

Nycomed (Switz)

$13.68 billion

Sep-11

Takeda (Japan)

Intellikine (US)

$190.0 million up front plus $120 million in contingent milestones

Exp Jan 2012

Teva Pharma Industries (Israel)

Infarmasa (Peru)

Undisclosed

Jan-11

Teva Pharma Industries (Israel)

Cephalon (US)

$6.8 billion

Oct-11

Teva (Israel)

Taiyo Pharma (Japan) 100% stake

$934.0 million

Jul-11

Teva (Israel)

CureTech (Israel) increases equity stake to 75%

$19.0 million plus $50 million R&D funding

Oct-11

Teva (Israel)

Teva-Kowa-Pharma, a joint venture with Kowa (Japan)

$150.0 million for Kowa's 50% share

Oct-11

The Medicines Company (US)

GeNO (US) undisclosed non-majority stake

Undisclosed

Dec-11

Valeant Pharma (Canada)

PharmaSwiss (Switz)

$480.0 million

Mar-11

Valeant Pharma (Canada)

Sanitas (Lithuania)

$444.4 million

Aug-11

Valeant (Canada)

Dermik (Canada & US) subsidiary of Sanofi (France)

$422.5 million

Dec-11

Valeant (Canada)

Ortho Dermatologics (unit of Johnson & Johnson) 

$345.0 million

Ann july; FTC appro gained Dec 12 2011

Valeant (Canada)

Afexa Life Sciences (Canada)

$76.9 million

Completed Dec 2011. Ann. Aug 31 in Battle with Paladin for control

Valeant (Canada)

iNova (Australia)

$703.8 million (including A$75 million contingent payment

Dec-11

Valeant (Canada)

ISTA Pharma (US)

$327.0 million

Ann Nov but rejected, and Valeant went hostile Dec 2011

ViroPharma (US)

DuoCort Pharma (Sweden)

$164.0 million

Nov-11

Watson Pharma (US)

Specifar Pharma (Greece)

$562.0 million plus 400 million-euro contingent

May-11

XTL Biopharma (Israel)

MinoGuard (Israel) technology

Undisclosed

Nov-11

Zydus Cadila (India)

Nesher Pharma generics unit of K-V Pharmaceutical US)

$60.0 million

Aug-11

Zydus Cadila (India)

Biochem (India)

Undisclosed

Dec-11